Research programme: RECK activators - Oncolys BioPharmaAlternative Names: Reversion-inducing-cysteine-rich protein with kazal motifs activators - Oncolys BioPharma
Latest Information Update: 22 Jun 2016
At a glance
- Originator Oncolys BioPharma
- Developer Kyoto University; Oncolys BioPharma
- Class Antineoplastics
- Mechanism of Action Gene stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer